HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of HSK7653 (as an add-on to metformin)
compared with linagliptin after 24 weeks, and the safety (up to 52 weeks) of HSK7653 in
Chinese patients with Type 2 Diabetes who have inadequate glycemic control on diet/exercise
therapy and metformin agent monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Sichuan Haisco Pharmaceutical Group Co., Ltd Sichuan Haisco Pharmaceutical Group Co., Ltd.